Guangxi LiuYao Group Co., Ltd

Equities

603368

CNE100001VR3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
22.79 CNY -0.04% Intraday chart for Guangxi LiuYao Group Co., Ltd +4.88% +20.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangxi Liuyao Gets Shanghai Bourse's Nod to Issue Shares MT
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangxi LiuYao Group Co., Ltd(XSSC:603368) added to S&P Global BMI Index CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Guangxi LiuYao Group Co., Ltd's Equity Buyback Plan announced on November 15, 2022. CI
Guangxi LiuYao Group Co., Ltd's Equity Buyback announced on November 15, 2022 has closed with 2,416,200 shares, representing 0.67% for CNY 51 million. CI
Guangxi LiuYao Group Co., Ltd announced that it expects to receive CNY 1 billion in funding CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Guangxi LiuYao Group Co., Ltd's Equity Buyback Plan announced on November 15, 2022. CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangxi LiuYao Sees 22.8% Jump in 2022 Profit MT
Tranche Update on Guangxi LiuYao Group Co., Ltd's Equity Buyback Plan announced on November 15, 2022. CI
Guangxi LiuYao to Repurchase Up to $14 Million Shares MT
Guangxi LiuYao Group Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares. CI
Guangxi LiuYao Group Co., Ltd authorizes a Buyback Plan. CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangxi Liuzhou Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guangxi Liuzhou Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guangxi Liuzhou Pharmaceutical Co., Ltd.(XSSC:603368) dropped from S&P Global BMI Index CI
Guangxi Liuzhou Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Guangxi Liuzhou Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Guangxi Liuzhou Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Chart Guangxi LiuYao Group Co., Ltd
More charts
Guangxi LiuYao Group Co Ltd, formerly Guangxi Liuzhou Pharmaceutical Co Ltd, is a China-based company mainly engaged in the sales of pharmaceuticals. The Company is mainly engaged in three businesses. The pharmaceutical wholesale business mainly distributes pharmaceutical products to medical and health institutions at all levels, pharmaceutical distribution enterprises and chain pharmacies. The pharmaceutical retail business provides sales and health services of various pharmaceutical products, medical devices and other pharmaceutical products to individual consumers through terminal pharmacies. The pharmaceutical industry business is mainly engaged in the production and research and development of pharmaceuticals and medical devices. The Company is also engaged in supply chain value-added services, pharmaceutical Internet services, terminal health services, etc.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.79 CNY
Average target price
31.29 CNY
Spread / Average Target
+37.30%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603368 Stock
  4. News Guangxi LiuYao Group Co., Ltd
  5. Guangxi LiuYao to Repurchase Up to $14 Million Shares